China Grand Pharmaceutical and Healthcare Holdings Limited

Grand Journey for A Healthier World

GP (HK) Announces Positive Profit Alert

The Expected Increase in Consolidated Net Profit Attributable to Owners of the Company for FY2020 No Less Than 40%

READ MORE

Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud

READ MORE

GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT

GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT

READ MORE

GP (HK) Acquires 80% Equity of Huachen BioTech, Accelerating the Globalization Development of Amino Acid Industry

GP (HK) Acquires 80% Equity of Huachen BioTech, Accelerating the Globalization Development of Amino Acid Industry

READ MORE

GP (HK) Announces 2021 interim Results, Profit Attributable to Owners of the Company Surges 67.4% to HK$1.2 billion, Continue to Increase R&D Investment, Proposes to Implement a Share Award Scheme

GP (HK) Announces 2021 interim Results, Profit Attributable to Owners of the Company Surges 67.4% to HK$1.2 billion, Continue to Increase R&D Investment, Proposes to Implement a Share Award Scheme

READ MORE

GP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System, Improving Product Pipeline in the Field of Cerebro-Cardiovascular Precision Interventional Diagnosis and Treatment

GP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System, Improving Product Pipeline in the Field of Cerebro-Cardiovascular Precision Interventional Diagnosis and Treatment

READ MORE

READ MORE

Popular News

27 Mar

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

READ MORE

27 Mar

Yuanda medicine gets sepsis innovative medicine again

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Results

READ MORE

27 Mar

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

READ MORE

27 Mar

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

READ MORE

Media Report

Yuanda medicine gets sepsis innovative medicine again

Shanghai Securities News China Securities Network2020-3-27